期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

ACEI联合β-受体阻滞剂治疗慢性心力衰竭56例疗效观察 被引量：3

下载PDF
导出
摘要 目的:探讨ACEI联合β-受体阻滞剂治疗慢性心力衰竭的疗效。方法:选择2006年1月-2011年12月笔者所在卫生院治疗的112例慢性心力衰竭患者,将以上患者随机分成两组,对照组给予双克、安体舒通,单硝酸异山梨醇酯、西地兰或地高辛等常规治疗,观察组在对照组常规治疗基础上加用ACEI与β-受体阻滞剂,两组均随访观察5个月。结果:对照组总有效率78.6%,观察组总有效率为92.9%,两组总有效率比较差异有统计学意义(P<0.05)。结论:ACEI联合β-受体阻滞剂能显著改善慢性心力衰竭患者心功能,提高生存质量,两种药物为国家基本药物,价格低廉,值得基层医院推广应用。
作者 孔军华
机构地区 巢湖市柘皋镇中心卫生院
出处 《中外医学研究》 2012年第30期26-27,共2页 CHINESE AND FOREIGN MEDICAL RESEARCH
关键词 ACEI Β-受体阻滞剂 慢性心力衰竭
分类号 R541.6 [医药卫生—心血管疾病]
  • 相关文献

参考文献5

二级参考文献20

  • 1陈瑾,胡大一,张麟,刘秀兰,吴雅峰,李静.卡维地洛对心脏β_1、β_2和α_1受体自身抗体及心功能的影响[J].中华心血管病杂志,2005,33(6):498-501. 被引量：69
  • 2张健,窦克非,杨跃进,韦丙奇,宋蓉,李佳,郑昕.静脉注射β受体阻滞剂治疗缺血性心脏病慢性心力衰竭急性加重临床经验总结[J].中国循环杂志,2006,21(3):175-177. 被引量：22
  • 3那开宪,余平.舒张性心力衰竭与收缩性心力衰竭治疗有何不同[J].首都医药,2007,14(06X):32-33. 被引量：5
  • 4Feuerstein GZ,Bril A.Ruffolo RR,et al.Protective effect of carvedilol in the myoeardium[J].Am J Cardio,1997,80(11A):41-45.
  • 5Packer M,Coats AJ,Fowler MB,el al.Effect of curvedilol on survival in severe chronic heart failure[J].N Engl J Med,2001,344(22):1 651-1 658.
  • 6Poole-Wilson PA,Swedberg K,Cleland JG,et al.Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failture in the carvedilol or Metoprolol European Trial(COMET):randomised controlled trial[J].Lancet,2003,362(2):7-13.
  • 7Sarafidis PA, Bakris GL. Antihypertensive treatment with beta- blocke~ and the spectrum of glycaemic control [ Jl. Quarterly J Med, 2006, 99 (7) : 431 - 436.
  • 8Owada A, Suda S, Hata T, et al. The effects of bisoprolol, a selec- tive beta-blocker, on glucose metabolism by long-term administration in essential hypertension [ J] . Clin Exp Hypertens, 2001,23(4): 305 -316.
  • 9R.efsgaard J, T homsen C, Andreasen F, et al . Carvedilol does not alter the insulin sensitivity in patients with congestive heart failure [J] . Eur J Heart Fail, 2002, 4(4):445 -453.
  • 10Kveiborg B, Christiansen B, Major-Petersen A, et al. Metabolic effects of beta-adrenoceptor antagonists with special emphasis on carvedilol[J]. Am J Cardiovasc Drugs, 2006, 6 (4) : 209 -217.

共引文献1870

同被引文献36

  • 1VOLPE M,SAVOIA C, De PAOLIS P,et al. The renin-angio- tensin system as a risk factor and therapeutic target for cardio- vascular and renal disease [ J ]. J Am Soc Nephrol, 2002,13: S173-S178.
  • 2OMBONI S, MALACCO E, PARATI G. Zofenopril plus hydro- chlorothiazide fixed combination in the treatment of hyper-tension and associated clinical conditions [ J ]. Cardiovascular Th- erapeutics ,2009,27 (4) :275-288.
  • 3JOANNIDES R, BELLIEN J,THURLURE C, et al. Fixed com- bination of perindopril and indapamide at low dose improves endothelial function in essential hypertensive patients after a- cute administration[J]. American Journal of Hypertension,2008, 21 (6) ;679-684.
  • 4KELLY A S, GONZALEZ-CAMPOY J M, RUDSER K D, et al. Carvedilol-lisinopril combination therapy and endothelial function in obese individuals with hypertension [ J ]. Journal of Clinical Hypertension,2012,14(2) :85-91.
  • 5JAMERSON K, WEBER M A, BAKRIS G L, et al. Benazepril plus amlodipine or hydroehlorothiazide for hypertension in high- risk patients[J]. N Engl J Med,2008,359(23):2417-428.
  • 6MANN J F, SCHMIEDER R E, MCQUEEN M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk ( the ONTARGET study) : a multicentre, random- ised,double-blind,controlled trial[J], l.ancet,2008,372(9638) : 547-553.
  • 7McMURRAY J, SOLOMON S, PIEPER K, et al. The Effect of valsartan, captopril, or both on atherosclerotic events after a- cute myocardial infarctionan analysis of the valsartan in acute myocardial infarction trial (VALIANT) [ J ]. Journal of the A- merican College of Cardiology, 2006,47 (4) : 726- 733.
  • 8MAGGIONI A P, LATINI R, CARSON P E, et al. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial ( Val- HEFT) [ J 1. American Heart Journal ,2(D5,149 (3) :548.
  • 9McMURRAY J, OSTERGREN J, SWEDBEIG K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angioten- sin-converting-enzyme inhibitors: the CHARM-Added trial [ J ]. Lancet, 2003,362 (9386) : 767" 771.
  • 10PFEFFER M A, McMURRAY J, VELAZQUEZ E J, et al. Val- sartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both [ J ]. New England Journal of Medicine, 2003,349 ( 20 ) : 1893-1906.

引证文献3

二级引证文献18

中外医学研究
2012年 第30期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部